Document:

Employment Agreement

 Exhibit 10.4 
 EMPLOYMENT AGREEMENT 
 THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into this
27th day of June, 2006 by and between Auxilium Pharmaceuticals, Inc. (the “Company”) and Armando Anido
(“Executive”). 
 WHEREAS, the Company desires to employ Executive, and Executive desires to be employed by the Company upon the
terms and conditions hereinafter set forth; 
 NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows:

 1 Employment. The Company hereby agrees to employ Executive, and Executive hereby accepts such employment and agrees to perform Executive’s
duties and responsibilities, in accordance with the terms, conditions and provisions hereinafter set forth. This Agreement shall be effective as of July 17, 2006 (the “Effective Date”) and shall continue until terminated in accordance
with Section 2 hereof. Nothing in this Agreement shall be construed as giving Executive any right to be retained in the employ of the Company, and Executive specifically acknowledges that Executive shall be an employee-at-will of the Company,
and thus subject to discharge at any time by the Company with or without cause and without compensation of any nature except as provided in Section 2 below. 
 1.1 Duties and Responsibilities. Commencing on the Effective Date, Executive shall serve as the Chief Executive Officer and President of the Company and shall perform all duties and accept all responsibilities
incident to such position as may be reasonably assigned to Executive by the Company’s Board of Directors (the “Board”). Executive has been elected by the Board to serve as a director of the Board subject to the By-laws of the Company
and Delaware General Corporation law. 
 1.2 Extent of Service. Executive agrees to use Executive’s best efforts to carry out
Executive’s duties and responsibilities under Section 1.1 hereof and, consistent with the other provisions of this Agreement, to devote substantially all of Executive’s business time, attention and energy thereto, except for vacations
in accordance with the company’s policy and absences due to temporary illness. The foregoing shall not be construed as preventing Executive from making investments in other businesses or enterprises, provided that Executive agrees not to become
engaged in any other business activity which, in the reasonable judgment of the Board, is likely to interfere with Executive’s ability to discharge Executive’s duties and responsibilities to the Company. Executive may serve on the board of
directors of other entities in accordance with the Company’s Corporate Governance Guidelines. 
 1.3 Base Salary. For all the
services rendered by Executive hereunder, the Company shall pay Executive a base salary (“Base Salary”) at the annual rate of $450,000, payable bi-weekly in installments at such times as the Company customarily pays its other senior level
executives. Executive’s Base Salary shall be reviewed annually for appropriate increases by the Board or Compensation Committee of the Board pursuant to the normal performance review policies for senior level executives. 
  

 1 

 1.4 Restricted Stock Units and Stock Options. 
 (a) Effective as of the Effective Date, Executive shall be granted a non-qualified option to purchase 500,000 shares (the “Option Grant”) of the
Company’s common stock at an exercise price per share equal to the last reported sale price of a share of the Company’s common stock on the Nasdaq National market on the Effective Date of this Agreement. Vesting of the Option Grant will be
over four years with twenty-five percent (25%) of the grant amount vesting in each of the four years, based on continued employment, beginning on the Effective Date. The Option Grant will be subject to the terms of the Company’s 2004
Equity Compensation Plan and the standard form of option agreement used by the Company for its employees. By approving this Agreement, the Board approves the grant of the foregoing stock option and the restricted stock units described below.

 (b) Effective as of the Effective Date, Executive shall be granted 200,000 shares of restricted stock units, and the lapsing of the
restrictions on such restricted stock units will be as follows based on continued employment: 
  

	 	•	 	First anniversary of Effective Date: 40,000 shares units of 200,000 restricted stock grant 

  

	 	•	 	Second anniversary of Effective Date: 40,000 shares units of 200,000 restricted stock grant 

  

	 	•	 	Third anniversary of Effective Date: 40,000 of shares units of 200,000 restricted stock grant 

  

	 	•	 	Fourth anniversary of Effective Date: 80,000 of shares units of restricted stock grant 

 1.5 Incentive Compensation. The Executive shall participate in short-term and long-term incentive programs established by the Company for its senior level executives generally, at levels determined by the Board
or the Compensation Committee of the Board. Executive’s incentive compensation shall be subject to the terms of the applicable plans and shall be determined based on Executive’s individual performance and Company performance as determined
by the Board or the Compensation Committee of the Board. Executive’s annual bonus eligibility shall be 65% of base salary, subject to achievement of goals to be mutually agreed upon by Executive and the Board or the Compensation Committee of
the Board, with a potential payout from 0 to 200% of the target amount depending upon achievement of the mutually agreed upon goals. For performance in the calendar year 2006, Executive will receive a guaranteed bonus in the amount of $146,250.

 1.6 Retirement and Welfare Plans. Executive shall participate in employee retirement and welfare benefit plans made available to
the Company’s senior level executives as a group or to its employees generally, as such retirement and welfare plans may be in effect from time to time and subject to the eligibility requirements of the plans. Nothing in this Agreement shall
prevent the Company from amending or terminating any retirement, welfare or other employee benefit plans or programs from time to time as the Company deems appropriate. 
  

 2 

 1.7 Reimbursement of Expenses; Vacation. Executive shall be provided with reimbursement of
reasonable expenses related to Executive’s employment by the Company on a basis no less favorable than that which may be authorized from time to time for senior level executives as a group, and shall be entitled to five (5) weeks of
vacation and three (3) personal days in accordance with the Company’s pay for time not worked policies. 
 1.8 Relocation
Expenses. The Company shall reimburse Executive for certain expenses related to his relocation as specifically set out in the letter agreement between the Company and Executive dated of even date herewith. 
 2. Termination. Executive’s employment shall terminate upon the occurrence of any of the following events: 
 2.1 Termination Without Cause Before A Change of Control. 
 (a) The Company may remove Executive at any time without Cause (as defined in Section 2.9) from the position in which Executive is employed hereunder upon not less than 30 days’ prior written notice to
Executive. The Company shall have discretion to terminate Executive’s employment during the notice period and pay continued Base Salary in lieu of notice. 
 (b) If Executive’s employment terminates as described in subsection (a) above and Executive executes and does not revoke a written release upon such removal, in a form provided by the Company, of any and all
claims against the Company and all related parties with respect to all matters arising out of Executive’s employment by the Company, or the termination thereof (the “Release”), Executive shall be entitled to receive the following
severance compensation, as long as Executive complies with the terms of Sections 4, 5, 6 and 7 below: 
 (i) Executive shall receive
severance payments in an amount equal to 1.0 times Executive’s annual Base Salary at the rate in effect at the time of Executive’s termination, plus bonus (average of last 2 years or most recent bonus amount, whichever is higher). The
severance amount shall be paid in equal monthly installments over the 12-month period following Executive’s termination of employment. 
 (ii) All outstanding stock options held by Executive at the date of Executive’s termination of employment that would have become exercisable during the 12-month period following Executive’s termination of employment shall become
fully exercisable on the date of termination and all restricted stock units, the restrictions on which would have lapsed during the 12-months period following Executive’s termination of employment, shall become fully vested and exercisable as
of the date of termination. 
 (iii) The Company shall pay the monthly COBRA medical insurance cost (less any required employee payments
calculated as if Executive had continued to be an employee) if Executive continues medical coverage under COBRA, for Executive, and, where applicable, his or her spouse and dependents, during the 12-month period following Executive’s
termination date. The Executive may elect COBRA continuation coverage according to the terms of the Company’s applicable medical plan for the period permitted under such plan. 
  

 3 

 (iv) Executive shall receive any benefits accrued in accordance with the terms of any applicable benefit
plans and programs of the Company. 
 (v) Except as otherwise required by Section 2.10, the benefits described in subsections
(i) and (iii) above shall begin within 30 days after Executive’s termination date (or at the end of the revocation period for the Release, if later). The Company shall provide the Release to Executive on or before the termination
date, and Executive shall execute the Release during the time period permitted by applicable law. 
 (vi) Executive agrees that if Executive
fails to comply with Section 4, 5, 6 or 7 below, all payments under this Section 2.1 shall immediately cease. 
 2.2 Termination
Without Cause; Resignation for Good Reason After A Change of Control. 
 (a) If a Change of Control occurs and the Company terminates
Executive’s employment without Cause at any time upon or after a Change of Control or Executive resigns for Good Reason (as defined in Section 2.9) upon or at any time during the one-year period following the Change of Control, this
Section 2.2 shall apply. 
 (b) If Executive’s employment terminates as described in subsection (a) above and Executive
executes and does not revoke a Release, Executive shall be entitled to receive the following severance compensation, as long as Executive complies with the terms of Sections 4, 5, 6 and 7 below: 
 (i) Executive shall receive a lump sum severance payment in an amount equal to (A) 1.50 times Executive’s annual Base Salary at the rate in
effect at the time of Executive’s termination, plus (B) 1.50 times Executive’s average annual bonus paid by the Company to Executive for the two fiscal years preceding Executive’s termination of employment or the most recent
bonus, whichever is higher. 
 (ii) The Company shall pay the monthly COBRA medical insurance cost (less any required employee payments
calculated as if Executive had continued to be an employee) if Executive continues medical coverage under COBRA, for Executive, and, where applicable, his or her spouse and dependents, during the 18-month period following Executive’s
termination date. The Executive may elect COBRA continuation coverage according to the terms of the Company’s applicable medical plan for the period permitted under such plan. 
 (iii) All outstanding stock options held by Executive at the date of Executive’s termination of employment shall become fully exercisable on the
date of termination and all stock awards (including restricted stock units) held by Executive at the date of Executive’s termination of employment shall become fully vested and exercisable as of the date of termination. 
  

 4 

 (iv) Executive shall receive any benefits accrued in accordance with the terms of any applicable benefit
plans and programs of the Company. 
 (v) Except as otherwise required by Section 2.10, the lump sum payment described in subsection
(i) shall be made, and the monthly payments described in subsection (ii) above shall begin, within 30 days after Executive’s termination date (or at the end of the revocation period for the Release, if later). The Company shall
provide the Release to Executive on or before the termination date, and Executive shall execute the Release during the time period permitted by applicable law.  
 (c) Executive agrees that if Executive materially breaches Section 4, 5, 6 or 7 below, all payments under this Section 2.2 shall immediately cease. 
 2.3 Increase in Payments Upon a Change of Control. 
 (a) Anything in this Agreement to the contrary notwithstanding, in the event that it shall be determined that any payment or distribution by the Company to or for the benefit of Executive, whether paid or payable or
distributed or distributable pursuant to the terms of this Agreement or otherwise (a “Payment”), would constitute an “excess parachute payment” within the meaning of Section 280G of the Code, the Company shall pay to
Executive an additional amount (the “Gross-Up Payment”) such that the net amount retained by Executive after deduction of any excise tax imposed under Section 4999 of the Code, and any federal, state and local income tax, employment
tax and excise tax imposed upon the Gross-Up Payment, shall be equal to the Payment. For purposes of determining the amount of the Gross-Up Payment, unless Executive specifies that other rates apply, Executive shall be deemed to pay federal income
tax and employment taxes at the highest marginal rate of federal income and employment taxation in the calendar year in which the Gross-Up Payment is to be made and state and local income taxes at the highest marginal rate of taxation in the state
and locality of Executive’s residence on Executive’s termination date, net of the maximum reduction in federal income taxes that may be obtained from the deduction of such state and local taxes. 
 (b) All determinations to be made under this Section 2.3 shall be made by the Company’s independent public accountant immediately prior to the
Change of Control or by another independent public accounting firm mutually selected by the Company and Executive before the date of the Change of Control (the “Accounting Firm”), which firm shall provide its determinations and any
supporting calculations both to the Company and Executive within 20 days after Executive’s termination date. Any such determination by the Accounting Firm shall be binding upon the Company and Executive. 
 (c) The Company shall pay the Gross-Up Payment as and when the related excise tax under section 4999 of the Code (“Excise Tax”) is incurred.
The Gross-Up Payment shall be paid in accordance with Section 409A of the Code, to the extent applicable. If required in order to comply with Section 409A of the Code, (i) the Gross-Up Payment attributable to Payments other than
severance compensation shall be paid in a lump sum payment upon the closing of the Change of Control, subject to Section 2.10 below, if applicable, and (ii) the Gross-Up Payment attributable to severance compensation shall be paid in a
lump sum payment on the first day on which severance compensation is paid. If the amount of a Gross-Up Payment cannot 
  

 5 

 be fully determined by the date on which the applicable portion of the Payment becomes subject to the Excise Tax
(“Payment Date”), the Company shall pay to the Employee by the Payment Date an estimate of such Gross-Up Payment, as determined by the Accounting Firm, and the Company shall pay to the Employee the remainder of such Gross-Up Payment (if
any) as soon as the amount can be determined, but in no event later than 20 days after the Payment Date. 
 (d) All of the fees and expenses
of the Accounting Firm in performing the determinations referred to in this Section 2.3 shall be borne solely by the Company. The Company agrees to indemnify and hold harmless the Accounting Firm from any and all claims, damages and expenses
resulting from or relating to its determinations pursuant to this Section 2.3, except for claims, damages or expenses resulting from the gross negligence or willful misconduct of the Accounting Firm. 
 2.4 Voluntary Termination. Executive may voluntarily terminate Executive’s employment for any reason upon 30 days’ prior written notice.
In such event, after the effective date of such termination, except as provided in Section 2.2 with respect to a resignation for Good Reason, no further payments shall be due under this Agreement, except that Executive shall be entitled to any
benefits accrued in accordance with the terms of any applicable benefit plans and programs of the Company. 
 2.5 Disability. The
Company may terminate Executive’s employment if after the Company has provided reasonable accommodation for Executive to perform essential job functions, Executive has been unable to perform the material duties of Executive’s employment
for a period of 90 days in any 12-month period because of physical or mental injury or illness (“Disability”); provided, however, that the Company shall continue to pay Executive’s Base Salary until the Company acts to terminate
Executive’s employment. Executive agrees, in the event of a dispute under this Section 2.5 relating to Executive’s Disability, to submit to a physical examination by a licensed physician jointly selected by the Board and Executive. If
the Company terminates Executive’s employment for Disability, no further payments shall be due under this Agreement, except that Executive shall be entitled to any benefits accrued in accordance with the terms of any applicable benefit plans
and programs of the Company. 
 2.6 Death. If Executive dies while employed by the Company, the Company shall pay to Executive’s
executor, legal representative, administrator or designated beneficiary, as applicable, any benefits accrued under the Company’s benefit plans and programs. Otherwise, the Company shall have no further liability or obligation under this
Agreement to Executive’s executors, legal representatives, administrators, heirs or assigns or any other person claiming under or through Executive. 
 2.7 Cause. The Company may terminate Executive’s employment at any time for Cause (as defined in Section 2.9) upon written notice to Executive, in which event all payments under this Agreement shall
cease. Executive shall be entitled to any benefits accrued before Executive’s termination in accordance with the terms of any applicable benefit plans and programs of the Company. 
 2.8 Notice of Termination. Any termination of Executive’s employment shall be communicated by a written notice of termination to the other
party hereto given in accordance 
  

 6 

 with Section 11. The notice of termination shall (i) indicate the specific termination provision in this
Agreement relied upon, (ii) briefly summarize the facts and circumstances deemed to provide a basis for a termination of employment and the applicable provision hereof, and (iii) specify the termination date in accordance with the
requirements of this Agreement. 
 2.9 Definitions. 
 (a) “Cause” shall mean any of the following grounds for termination of Executive’s employment: 
 (i) Executive shall have been convicted of, or entered a plea of guilty to, a felony, 
 (ii) Executive
intentionally and continually fails to perform Executive’s reasonably assigned material duties to the Company (other than a failure resulting from Executive’s incapacity due to physical or mental illness), which failure has continued for a
period of at least 30 days after a written notice of demand for substantial performance, signed by a duly authorized officer of the Company, has been delivered to Executive specifying the manner in which Executive has failed substantially to
perform, 
 (iii) Executive engages in willful misconduct in the performance of Executive’s duties, or 
 (iv) Executive materially breaches Section 4, 5, 6 or 7 below. 
 (b) “Change of Control” as used herein, a “Change of Control” shall be deemed to have occurred if: 
 (i) Any “person” (as such term is used in sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) becomes a “beneficial owner” (as defined in
Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than 50% of the voting power of the then outstanding securities of the Company; provided that a Change of Control shall not be deemed to occur
as a result of a transaction in which the Company becomes a subsidiary of another corporation and in which the stockholders of the Company, immediately prior to the transaction, will beneficially own, immediately after the transaction, shares
entitling such stockholders to more than 50% of all votes to which all stockholders of the parent corporation would be entitled in the election of directors; or 
 (ii) The consummation of (A) a merger or consolidation of the Company with another corporation where the stockholders of the Company, immediately prior to the merger or consolidation, will not beneficially own,
immediately after the merger or consolidation, shares entitling such stockholders to more than 50% of all votes to which all stockholders of the surviving corporation would be entitled in the election of directors, (B) a sale or other
disposition of all or substantially all of the assets of the Company, or (C) a liquidation or dissolution of the Company. 
  

 7 

 (iii) After the Effective Date, directors are elected such that a majority of the members of the Board
shall have been members of the Board for less than two years, unless the election or nomination for election of each new director who was not a director at the beginning of such two-year period was approved by a vote of at least two-thirds of the
directors then still in office who were directors at the beginning of such period. 
 (c) “Code” shall mean the Internal
Revenue Code of 1986, as amended. 
 (d) “Good Reason” shall mean the occurrence of any of the following events or
conditions, unless Executive has expressly consented in writing thereto, or except as a result of Executive’s physical or mental incapacity or as described in the last sentence of this subsection (c): 
 (i) a reduction in Executive’s Base Salary; 
 (ii) a substantial reduction of Executive’s duties and responsibilities hereunder; 
 (iii) the Company requires that
Executive’s principal office location be moved to a location more than 50 miles from Executive’s principal office location immediately before the change; or 
 (iv) failure of a successor company to comply with Section 12(b) hereof. 
 Notwithstanding the foregoing, Executive
shall not have Good Reason for termination unless Executive gives written notice of termination for Good Reason within 30 days after the event giving rise to Good Reason occurs and the Company does not correct the action or failure to act that
constitutes the grounds for Good Reason, as set forth in Executive’s notice of termination, within 30 days after the date on which Executive gives written notice of termination. 
 2.10 Required Postponement for Specified Executives. 
 (a) If Executive is considered a Specified Executive (as defined below) and payment of any amounts under this Agreement is required to be delayed for a period of six months after separation from service pursuant to
Section 409A of the Code, payment of such amounts shall be delayed as required by section 409A, and the accumulated postponed amounts, with accrued interest as described below, shall be paid in a lump sum payment within five days after the end
of the six month period. If Executive dies during the postponement period prior to the payment of benefits, the amounts postponed on account of Section 409A, with accrued interest as described in subsection (b) below, shall be paid to the
personal representative of Executive’s estate within 60 days after the date of Executive’s death. 
 (b) If payment of any amounts
under this Agreement is required to be delayed pursuant to section 409A of the Code, the Company shall pay interest on the postponed payments from the date on which the amounts otherwise would have been paid to the date on which such amounts are
paid at an annual rate equal to the rate announced by Deutsche Bank (or its successor) as its “prime rate” as of Executive’s Termination Date. 
  

 8 

 (c) The term “Specified Executive” means an employee who, at any time during the 12-month
period ending on the identification date (defined below), is (i) an officer of the Company or a member of its controlled group (as determined for purposes of section 416(i) of the Code) who has annual compensation greater than $135,000 (or such
other amount as may be in effect under Section 416(i)(1) of the Code), (ii) a 5% owner of the Company or (iii) a 1% owner of the Company who has annual compensation greater than $150,000. The identification date shall be each
December 31, and the determination of Specified Executives as of such identification date shall apply for the 12-month period following April 1 after the identification date. The determination of Specified Executives, including the number
and identity of persons considered officers, shall be made by the Company in accordance with the provisions of Sections 416(i) and 409A of the Code and the regulations issued thereunder. 
 3. Non-Exclusivity of Rights. Nothing in this Agreement shall prevent or limit Executive’s continuing or future participation in or rights under any benefit, bonus, incentive or other plan or program
provided by the Company and for which Executive may qualify; provided, however, that if Executive becomes entitled to and receives the payments provided for in Section 2 of this Agreement, Executive hereby waives Executive’s right to
receive payments under any severance plan or similar program applicable to all employees of the Company. 
 4. Confidentiality. Executive agrees that
Executive’s services to the Company and its subsidiaries and any successors or assigns (collectively, the “Employer”) were and are of a special, unique and extraordinary character, and that Executive’s position places Executive
in a position of confidence and trust with the Employer’s customers and employees. Executive also recognizes that Executive’s position with the Employer will give Executive substantial access to Confidential Information (as defined below),
the disclosure of which to competitors of the Employer would cause the Employer to suffer substantial and irreparable damage. Executive recognizes, therefore, that it is in the Employer’s legitimate business interest to restrict
Executive’s use of Confidential Information for any purposes other than the discharge of Executive’s employment duties at the Employer, and to limit any potential appropriation of Confidential Information by Executive for the benefit of
the Employer’s competitors and to the detriment of the Employer. Accordingly, Executive agrees as follows: 
 (a) Executive will not at
any time, whether during or after the termination of Executive’s employment, reveal to any person or entity any of the trade secrets or confidential information of the Employer or of any third party which the Employer is under an obligation to
keep confidential (including but not limited to trade secrets or confidential information respecting inventions, products, designs, methods, know-how, techniques, systems, processes, software programs, works of authorship, customer lists, projects,
plans and proposals) (“Confidential Information”), except as may be required in the ordinary course of performing Executive’s duties as an employee of the Employer, and Executive shall keep secret all matters entrusted to Executive
and shall not use or attempt to use any such information in any manner which may injure or cause loss or may be calculated to injure or cause loss whether directly or indirectly to the Employer. 
 (b) The above restrictions shall not apply to: (i) information that at the time of disclosure is in the public domain through no fault of Executive;
(ii) information received from a third party outside of the Employer that was disclosed without a breach of any confidentiality 
  

 9 

 obligation; (iii) information approved for release by written authorization of the Employer; or
(iv) information that may be required by law or an order of any court, agency or proceeding to be disclosed; provided Executive shall provide the Employer notice of any such required disclosure once Executive has knowledge of it and will help
the Employer to the extent reasonable to obtain an appropriate protective order. 
 (c) Further, Executive agrees that during
Executive’s employment Executive shall not take, use or permit to be used any notes, memoranda, reports, lists, records, drawings, sketches, specifications, software programs, data, documentation or other materials of any nature relating to any
matter within the scope of the business of the Employer or concerning any of its dealings or affairs otherwise than for the benefit of the Employer. Executive further agrees that Executive shall not, after the termination of Executive’s
employment, use or permit to be used any such notes, memoranda, reports, lists, records, drawings, sketches, specifications, software programs, data, documentation or other materials, it being agreed that all of the foregoing shall be and remain the
sole and exclusive property of the Employer and that, immediately upon the termination of Executive’s employment, Executive shall deliver all of the foregoing, and all copies thereof, to the Employer, at its main office. 
 (d) Executive agrees that upon the termination of Executive’s employment with the Employer, Executive will not take or retain without written
authorization any documents, files or other property of the Employer, and Executive will return promptly to the Employer any such documents, files or property in Executive’s possession or custody, including any copies thereof maintained in any
medium or format. Executive recognizes that all documents, files and property which Executive has received and will receive from the Employer, including but not limited to scientific research, customer lists, handbooks, memoranda, product
specifications, and other materials (with the exception of documents relating to benefits to which Executive might be entitled following the termination of Executive’s employment with the Employer), are for the exclusive use of the Employer and
employees who are discharging their responsibilities on behalf of the Employer, and that Executive has no claim or right to the continued use, possession or custody of such documents, files or property following the termination of Executive’s
employment with the Employer. 
 5. Intellectual Property. 
 (a) If at any time or times during Executive’s employment Executive shall (either alone or with others) make, conceive, discover or reduce to practice any invention, modification, discovery, design, development,
improvement, process, software program, work of authorship, documentation, formula, data, technique, know-how, secret or intellectual property right whatsoever or any interest therein (whether or not patentable or registrable under copyright or
similar statutes or subject to analogous protection) (herein called “Developments”) that (i) relates to the business of the Employer or any customer of or supplier to the Employer or any of the products or services being developed,
manufactured or sold by the Employer or which may be used in relation therewith, (ii) results from tasks assigned to Executive by the Employer or (iii) results from the use of premises or personal property (whether tangible or intangible)
owned, leased or contracted for by the Employer, such Developments and the benefits thereof shall immediately become the sole and absolute property of the Employer and its assigns, and Executive shall promptly disclose to the Employer (or any
persons designated by it) each such 
  

 10 

 Development, and Executive hereby assigns any rights Executive may have or acquire in the Developments and benefits
and/or rights resulting therefrom to the Employer and its assigns without further compensation and shall communicate, without cost or delay, and without publishing the same, all available information relating thereto (with all necessary plans and
models) to the Employer. 
 (b) Upon disclosure of each Development to the Employer, Executive will, during Executive’s employment and
at any time thereafter, at the request and cost of the Employer, sign, execute, make and do all such deeds, documents, acts and things as the Employer and its duly authorized agents may reasonably require: 
 (i) to apply for, obtain and vest in the name of the Employer alone (unless the Employer otherwise directs) letters patent, copyrights or other analogous
protection in any country throughout the world and when so obtained or vested to renew and restore the same; and 
 (ii) to defend any
opposition proceedings in respect of such applications and any opposition proceedings or petitions or applications for revocation of such letters patent, copyright or other analogous protection. 
 (c) In the event the Employer is unable, after reasonable effort, to secure Executive’s signature on any letters patent, copyright or other
analogous protection relating to a Development, whether because of Executive’s physical or mental incapacity or for any other reason whatsoever, Executive hereby irrevocably designates and appoints the Employer and its duly authorized officers
and agents as Executive’s agent and attorney-in-fact, to act for and on Executive’s behalf and stead to execute and file any such application or applications and to do all other lawfully permitted acts to further the prosecution and
issuance of letter patents, copyright and other analogous protection thereon with the same legal force and effect as if executed by Executive. 
 6.
Non-Competition. While Executive is employed at the Employer and for a period of one year after termination of Executive’s employment (for any reason whatsoever, whether voluntary or involuntarily), Executive will not, without the prior
written approval of the Board, whether alone or as a partner, officer, director, consultant, agent, employee or stockholder of any company or other commercial enterprise, directly or indirectly engage in any business or other activity in the United
States or Canada which competes with the Employer in the sale of the pharmaceutical or other products being manufactured, marketed, distributed or developed by the Employer while Executive is employed by Employer. The foregoing prohibition shall not
prevent Executive’s employment or engagement after termination of Executive’s employment by any company or business organization, as long as the activities of any such employment or engagement, in any capacity, do not involve work on
matters related to the products being developed, manufactured, or marketed by the Employer during Executive’s employment with the Employer. Executive shall be permitted to own securities of a public company not in excess of five percent of any
class of such securities and to own stock, partnership interests or other securities of any entity not in excess of five percent of any class of such securities and such ownership shall not be considered to be in competition with the Employer.

  

 11 

 7. Non-Solicitation. While Executive is employed at the Employer and for a period of one (1) year after
termination of such employment (for any reason, whether voluntary or involuntarily), Executive agrees that Executive will not: 
 (a) directly
or indirectly solicit, entice or induce any customer to become a customer of any other person, firm or corporation with respect to products then sold or under development by the Employer or to cease doing business with the Employer, and Executive
shall not approach any such person, firm or corporation for such purpose or authorize or knowingly approve the taking of such actions by any other person; or 
 (b) directly or indirectly solicit or recruit any employee of the Employer to work for a third party other than the Employer (excluding newspaper or similar print or electronic solicitations of general circulation).

 8. General Provisions. 
 (a) Executive
acknowledges and agrees that the type and periods of restrictions imposed in Sections 4, 5, 6 and 7 of this Agreement are fair and reasonable, and that such restrictions are intended solely to protect the legitimate interests of the Employer, rather
than to prevent Executive from earning a livelihood. Executive recognizes that the Employer competes worldwide, and that Executive’s access to Confidential Information makes it necessary for the Employer to restrict Executive’s
post-employment activities in any market in which the Employer competes, and in which Executive’s access to Confidential Information and other proprietary information could be used to the detriment of the Employer. In the event that any
restriction set forth in this Agreement is determined to be overbroad with respect to scope, time or geographical coverage, Executive agrees that such a restriction or restrictions should be modified and narrowed, either by a court or by the
Employer, so as to preserve and protect the legitimate interests of the Employer as described in this Agreement, and without negating or impairing any other restrictions or agreements set forth herein. 
 (b) Executive acknowledges and agrees that if Executive should breach any of the covenants, restrictions and agreements contained herein, irreparable
loss and injury would result to the Employer, and that damages arising out of such a breach may be difficult to ascertain. Executive therefore agrees that, in addition to all other remedies provided at law or at equity, the Employer shall be
entitled to have the covenants, restrictions and agreements contained in Sections 4, 5, 6, and 7 specifically enforced (including, without limitation, by temporary, preliminary, and permanent injunctions and restraining orders) by any state or
federal court in the Commonwealth of Pennsylvania having equity jurisdiction and Executive agrees to subject Executive to the jurisdiction of such court. 
 (c) Executive agrees that if the Employer fails to take action to remedy any breach by Executive of this Agreement or any portion of the Agreement, such inaction by the Employer shall not operate or be construed as a
waiver of any subsequent breach by Executive of the same or any other provision, agreement or covenant. 
  

 12 

 (d) Executive acknowledges and agrees that the payments and benefits to be provided to Executive under
this Agreement are provided as consideration for the covenants in Sections 4, 5, 6, and 7 hereof. 
 9. Survivorship. The respective rights and
obligations of the parties under this Agreement shall survive any termination of Executive’s employment to the extent necessary to the intended preservation of such rights and obligations. 
 10. Mitigation. Executive shall not be required to mitigate the amount of any payment or benefit provided for in this Agreement by seeking other employment or
otherwise and there shall be no offset against amounts due Executive under this Agreement on account of any remuneration attributable to any subsequent employment that Executive may obtain. 
 11. Notices. All notices and other communications required or permitted under this Agreement or necessary or convenient in connection herewith shall be in writing
and shall be deemed to have been given when hand delivered or mailed by registered or certified mail, as follows (provided that notice of change of address shall be deemed given only when received): 
 If to the Company, to: 
 Auxilium
Pharmaceuticals, Inc. 
 40 Valley Stream Parkway 
 Malvern, PA 19355 
 If to Executive, to: 
 Armando Anido 
 14500 High Meadow Way

 North Potomac, MD 20878 
 or to such other
names or addresses as the Company or Executive, as the case may be, shall designate by notice to each other person entitled to receive notices in the manner specified in this Section. 
 12. Contents of Agreement; Amendment and Assignment. 
 (a) This Agreement sets forth the entire
understanding between the parties hereto with respect to the subject matter hereof and supercedes any and all prior agreements and understandings concerning Executive’s employment by the Company and cannot be changed, modified, extended or
terminated except upon written amendment approved by the Board and executed on its behalf by a duly authorized officer and by Executive. 
 (b) All of the terms and provisions of this Agreement shall be binding upon and inure to the benefit of and be enforceable by the respective heirs, executors, administrators, legal representatives, successors and assigns of the parties
hereto, except that the duties and responsibilities of Executive under this Agreement are of a personal nature and shall not be assignable or delegatable in whole or in part by Executive. The Company shall require any successor (whether direct or
indirect, by purchase, merger, consolidation, reorganization or 
  

 13 

 otherwise) to all or substantially all of the business or assets of the Company, within 15 days of such succession,
expressly to assume and agree to perform this Agreement in the same manner and to the same extent as the Company would be required to perform if no such succession had taken place. 
 13. Severability. If any provision of this Agreement or application thereof to anyone or under any circumstances is adjudicated to be invalid or unenforceable in any jurisdiction, such invalidity or
unenforceability shall not affect any other provision or application of this Agreement which can be given effect without the invalid or unenforceable provision or application and shall not invalidate or render unenforceable such provision or
application in any other jurisdiction. If any provision is held void, invalid or unenforceable with respect to particular circumstances, it shall nevertheless remain in full force and effect in all other circumstances. 
 14. Remedies Cumulative; No Waiver. No remedy conferred upon a party by this Agreement is intended to be exclusive of any other remedy, and each and every such
remedy shall be cumulative and shall be in addition to any other remedy given under this Agreement or now or hereafter existing at law or in equity. No delay or omission by a party in exercising any right, remedy or power under this Agreement or
existing at law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may be exercised by such party from time to time and as often as may be deemed expedient or necessary by such party in its sole discretion.

 15. Withholding. All payments under this Agreement shall be made subject to applicable tax withholding, and the Company shall withhold from any
payments under this Agreement all federal, state and local taxes as the Company is required to withhold pursuant to any law or governmental rule or regulation. Except as otherwise provided by Section 2.3, Executive shall bear all expense of,
and be solely responsible for, all federal, state and local taxes due with respect to any payment received under this Agreement. 
 16. Miscellaneous.
This Agreement may be executed in counterparts, each of which is an original. It shall not be necessary in making proof of this Agreement or any counterpart hereof to produce or account for any of the other counterparts. 
 17. Governing Law. This Agreement shall be governed by and interpreted under the laws of the Commonwealth of Pennsylvania without giving effect to any conflict of
laws provisions or canons of construction that construe agreements against the draftsperson. 
 18. Section 409A of the Code. This Agreement is
intended to comply with Section 409A of the Code and its corresponding regulations, to the extent applicable. Notwithstanding anything 
  

 14 

 in this Agreement to the contrary, payments may only be made under this Agreement upon an event and in a manner permitted
by Section 409A of the Code, to the extent applicable. 
 IN WITNESS WHEREOF, the undersigned, intending to be legally bound, have executed this
Agreement as of the date first above written. 
  

			
	AUXILIUM PHARMACEUTICALS, INC.
		
	By:	 	 /s/ James E. Fickenscher

	Name:	 	James E. Fickenscher
	Title:	 	Chief Financial Officer
	
	EXECUTIVE
	
	 /s/ Armando Anido

	ARMANDO ANIDO

  

 15Letter Agreement

 Exhibit 10.5 
 

 
 Mr. Armando Anido 
 14500 High Meadow Way 
 North Potomac, MD 20878 
 June 26, 2006 
 Dear Armando: 
 In order to assist you with
your relocation to the Malvern, PA area, Auxilium Pharmaceuticals, Inc. (the “Company”) hereby agrees to reimburse you for the expenses set out below within thirty (30) days of submission of written documentation and receipts
evidencing such expenses. 
 1. Home Search: 
  

	 	•	 	Transportation, room charges, meals, and telephone expenses for you and your spouse will be reimbursed for up to two (2) trips not to exceed seven (7) days in total.

  

	 	•	 	Cost of rental car. 

 2. Sale of
Home: 
 The Company will reimburse the following expenses related to the sale of your current home: 
  

	 	•	 	Commission paid to licensed real estate broker, based on rate that is normal and customary; 

  

	 	•	 	Appraisal fee; 

  

	 	•	 	Advertising expense if no realtor’s fee is incurred; 

  

	 	•	 	Normal, customary or reasonable attorney’s fees directly related to the sale; 

  

	 	•	 	Federal documentary tax stamps; 

  

	 	•	 	Recording of discharge of mortgage; 

  

	 	•	 	Penalty for prepayment of mortgage; 

  

	 	•	 	Other conveyance expenses when it is the local custom for the seller to pay such costs to include: 

  

	 	•	 	State or local tax on the transfer of real estate, 

  

	 	•	 	Abstract, title or title insurance costs, 

  

	 	•	 	Tax search, 

  

	 	•	 	Survey expense, 

  

	 	•	 	Inspection fees, 

  

	 	•	 	Closing or transfer fee, 

  

	 	•	 	Escrow retainer fee. 

 Mr. Armando Anido 
 Page 2 
 Other settlement
expenses must have prior approval of the Vice President of Human Resources 
 3. Closing Cost Reimbursement for New Home: 
  

	 	•	 	If you purchase or contract to purchase a home in the Malvern, PA area within twelve (12) months following the effective date of your employment with the Company, the Company
will reimburse the following expenses: 

  

	 	•	 	Attorney’s fees (limited to normal closing services); 

  

	 	•	 	Mortgage Originator’s fees (points) discount points and VA seller points up to a maximum of 1% total loan amount; 

  

	 	•	 	Mortgage tax; 

  

	 	•	 	Recording fees; 

  

	 	•	 	Mandated appraisal and inspection fees; 

  

	 	•	 	Bank or escrow service fees (not actual escrow funds); 

  

	 	•	 	Other closing costs which are normally charged to the buyer such as: 

  

	 	•	 	Property survey expense (if required by lender), 

  

	 	•	 	Tax on transfer or real estate, 

  

	 	•	 	Inspection fees, 

  

	 	•	 	Title report and title insurance, 

 Other settlement
expenses must have prior approval of the Vice President of Human Resources 
 4. Temporary Living Assistance:

  

	 	•	 	You will be provided relocation assistance for reasonable expenses including hotel room/executive housing charges, breakfast and dinner expenses, and incidental expenses of laundry
and phone calls home for a period of sixty (60) days. This period may be extended an additional thirty (30) days by approval of the Chairman of the Board of Directors of the Company. 

  

	 	•	 	The Company will provide relocation assistance for your family’s hotel/executive housing, meals and incidental living expenses for a maximum of two (2) weeks in the new
location while awaiting the arrival of household goods or availability of permanent housing. 

  

	 	•	 	Travel expenses may also be reimbursed for a reasonable number of trips to the old location for the purpose of closing your affairs and accompanying the family to the new location.

 5. Movement of Household Goods 
  

	 	•	 	The Company will pay for the cost of transporting (including packing and unpacking) the household and personal effects and those of other household members.

  

	 	•	 	The Company will pay for the shipment of one automobile. 

  

	 	•	 	Mileage reimbursement will be provided and will apply to car(s) driven to the new location. 

 Mr. Armando Anido 
 Page 3 
 6. Incidental Expenses

 The Company will make to you a one-time payment in the amount of $10,000 for incidental expenses no later than August 15, 2006.
The amount will be included in the gross-up allowance described in paragraph 7 below. 
 7. Taxable Income Reimbursement: 
 Some of the reimbursements and allowances provided by the Company will be taxable income and must be included in the W-2 summary of earnings. To help offset this extra
tax expense, a special gross-up allowance will be calculated to cover the estimated tax liability (federal, state, and local) resulting from the relocation assistance. This allowance will be paid so long as you remain in the employ of the Company
for 26 weeks following the effective date of your employment. The payment is in the form of additional income and withholding on your W-2 (this is not income for any benefit plan calculations or pension plan benefits). 
 Please sign below to indicate your agreement with and acceptance of the terms of this agreement. 
 Sincerely, 
  

			
	AUXILIUM PHARMACEUTICALS, INC.
		
	By:	 	 /s/ James E. Fickenscher

	Name:	 	James E. Fickenscher
	Title:	 	Chief Financial Officer
	
	AGREED AND ACCEPTED:
	
	 /s/ Armando Anido

	Armando Anido

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]